



# Macquarie Australia Conference

---

Healing. Redefined.

May 2025

Personal use only

This presentation has been prepared by PolyNovo Limited and is provided for general information purposes only. No party other than PolyNovo has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation.

This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. PolyNovo Limited makes no warranty or representation (express or implied) as to the accuracy, reliability or completeness of the information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even elimination, depending on further research and investigation. Further, any opinions (including any forward-looking statements) expressed in this presentation are subject to change without notice. PolyNovo and its directors, officers, employees, advisers and agents shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, or contained in or derived from, or for any omissions from this presentation, except liability under statute that cannot be excluded.

This presentation, including the information contained in this disclaimer, does not form part of any offer, invitation or recommendation in respect of shares, or an offer, invitation or recommendation to sell, or a solicitation of any offer to buy, shares in the United States, or in any other jurisdiction in which, or to any person to whom, such an offer would be illegal.

This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks, uncertainties and assumptions, many of which are outside the control of PolyNovo. Actual values, results or events may be materially different to those expressed or implied in this presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No representation or warranty (express or implied) is made by PolyNovo or any of its directors, officers, employees, advisers or agents that any forecasts, projections, intentions, expectations or plans set out in this presentation will be achieved.

This Presentation has been authorised by the Board of Directors of PolyNovo Limited.

# Sales, Revenue and New Product Highlights

## Group Sales:

- March 2025: record monthly sales of **A\$11.9m**, up **71.1%** on STLY of **A\$6.9m**.
- Year to date (March 2025): sales of **A\$84.4m**, up **31.1%** on STLY of **A\$64.4m**.

## Group Revenue:


- March 2025: total monthly group revenue (including BARDA) of **A\$12.4m**, up **48.5%** on STLY of **A\$8.4m**.
- Year to date (March 2025): total group revenue of **A\$91.6m**, up **23.7%** on STLY of **A\$74.1m**.

## New Products:

- Expansion of the NovoSorb BTM and MTX portfolios continues in line with strategic plans:
  - March 2025: FDA 510(k) clearance for NovoSorb MTX (up to 6 mm), TGA (Australia) and CDSCO (India) clearance for NovoSorb MTX (2 mm).
  - May 2025: TGA (Australia) clearance for NovoSorb MTX (up to 6 mm).
- The next FDA filing is scheduled this financial year for NovoSorb BTM 6 mm.
- The Hernia program, along with other soft tissue reinforcement programs, is moving forward on the back of positive preclinical results.

# Global Growth Highlights

A\$(m) record monthly sales and revenue



## United States

- March 2025: record monthly sales of **A\$9.3m**, up **92.6%** on STLY of **A\$4.8m**.
- Year to date (March 2025): sales of **A\$64.4m**, up **32.3%** on STLY of **A\$48.7m**.
- April 2025: record NovoSorb MTX sales of **A\$880k**.
- **700+** customer accounts.

## United Kingdom

- March 2025: monthly sales of **A\$0.9m**, up **139.8%** on STLY of **A\$0.4m**.
- Year to date (March 2025): sales of **A\$5.5m**, up **62.4%** on STLY of **A\$3.4m**.

## India

- March 2025: monthly sales of **A\$133k**, up **97.2%** on STLY of **A\$68k**.
- Year to date (March 2025): sales of **A\$0.9m**.
- April 2025: record monthly sales of **A\$207k**.
- **300+** hospital accounts, 16 tenders won.

## Rest of World

- March 2025: monthly sales of **A\$2.6m**, up **22.6%** on STLY of **A\$2.2m**.
- Year to date (March 2025): sales of **A\$20.0m** up **27.2%** on STLY of **A\$15.7m**.

## BARDA:

- Completion of the BARDA pivotal trial for NovoSorb BTM remains on track.
- A hard data lock is anticipated for May.
- Full statistical analysis of the data generated will be undertaken to enable a premarket approval application with the US FDA for an on-label claim supporting the use of NovoSorb BTM in full thickness burns.

## Capital:

- U.S. debtor collections is improving significantly, as is cash flow from operations for the group.
- Cash on hand as of 30 April 2025 was A\$22.0m.
- Adjusting cash on hand as of 30 April 2025 by adding back overdue U.S. debtors (not at risk), less committed capex for completing the new facility, cash on hand would be: A\$24.2m (March 2025: A\$21.8m)
- We have enough capital to continue to execute on commitments and strategic plans.

## Other business:

- CEO recruitment process has commenced.
- Japan: distributor appointed.
- China: partners identified, discussions and meetings in China continue.

# Shifting the Standard of Care across the World

## U.K and Ireland

- Standard of care, market share leader

## Europe

- Surgeon networks driving expansion into new markets
- Market share leader in Germany, France, Turkey and close second in Spain

## U.S.

- Standard of care, market share leader.
- **NovoSorb MTX 510(k):**
  - September 2022: 2 mm
  - March 2025: up to 6 mm

## India

- Entered the Indian market in late 2022
- April 2024: NovoSorb BTM included in GEM Portal
- March 2025: NovoSorb MTX 2 mm CDSCO clearance

## China\* and Japan\*

- Global #2 and #3 medical device markets

## Taiwan and Hong Kong

- 2020: First sale in Taiwan
- 2022: First sale in Hong Kong

## Australia and NZ

- Standard of care, market share leader
- **NovoSorb MTX TGA milestones:**
  - March 25: 2 mm
  - May 25: up to 6 mm

46 Countries

70,000+ Patients

340+ Independent articles and abstracts


 Current market  Current market and market leader  Market entry options being evaluated, \*seeking alliances

# NovoSorb<sup>®</sup>

Next Generation New Standard of Care

Platform technology:  
Graftable & Implantable

Capital efficient  
Growth and Scaling



mal use only




# NovoSorb®: From Platform Technology to Products

Burn Surgeons

Plastic and Reconstruction, Trauma Surgeons

General Surgeons



Regulatory filing, U.S. FDA



**CY25:**  
PolyNovo R&D centre.

